Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 0.57 |
| ▸ | POLG | P54098 | 1/20 | 0.45 |
| ▸ | DCK | P27707 | 15/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130892 | 1.00 | ALB (0.57) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL4590964 | 0.80 | ALB (0.46) | ALBPOLGCACNA1FLMNAMAPT | |
| SCHEMBL7549626 | 0.78 | ALB (0.57) | ALBPOLGDCK | |
| SCHEMBL8088509 | 0.76 | ALB (0.68) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL11563446 | 0.76 | LMNA (0.55) | ALBPOLGDCKLMNAMAPT | |
| SCHEMBL12149476 | 0.76 | ALB (0.72) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL7138994 | 0.76 | ALB (0.68) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL7138991 | 0.76 | ALB (0.68) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL10015806 | 0.76 | ALB (0.68) | ALBPOLGDCKCACNA1FLMNA | |
| SCHEMBL7138999 | 0.76 | ALB (0.68) | ALBPOLGDCKCACNA1FLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184702-A | Antiviral prodrugs and uses thereof | 上海柯君医药科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| EP-1545557-B1 | COMBINATION THERAPIES WITH L-FMAU FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20050196379-A1 | Combination therapies with L-FMAU for the treatment of hepatitis B virus infection | GILEAD SCIENCES, INC. | 2005-09-08 | — | — | US | disclosed |
| WO-2004006848-A2 | COMBINATION THERAPIES WITH FTC FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES , INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050196379-A1 | Combination therapies with L-FMAU for the treatment of hepatitis B virus infection | IFNG, OAT, EIF2AK2 | ALB 855/4885POLG 604/4885DCK 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.